Dialogical therapy plus treatment as usual versus treatment as usual in adults with distressing and persistent auditory hallucinations in the UK (Talking with Voices-II): a randomised controlled trial.

IF 21.1 1区 医学 Q1 PSYCHIATRY
Eleanor Longden, Alison Branitsky, Callum Glen, Verity Bell, Emmeline Joyce, Samantha E Bowe, Dirk Corstens, Rob Dudley, Amy Hardy, Bryony Sheaves, Richard Emsley, Melissa Pyle, Daniel Freeman, Wendy Jones, Anthony P Morrison
{"title":"Dialogical therapy plus treatment as usual versus treatment as usual in adults with distressing and persistent auditory hallucinations in the UK (Talking with Voices-II): a randomised controlled trial.","authors":"Eleanor Longden, Alison Branitsky, Callum Glen, Verity Bell, Emmeline Joyce, Samantha E Bowe, Dirk Corstens, Rob Dudley, Amy Hardy, Bryony Sheaves, Richard Emsley, Melissa Pyle, Daniel Freeman, Wendy Jones, Anthony P Morrison","doi":"10.1016/S2215-0366(26)00330-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Existing treatments for auditory hallucinations (hereafter voice hearing) among people with serious mental health problems (SMHPs; diagnoses include schizophrenia spectrum disorders, bipolar disorders, and personality disorders) show only modest clinical benefits, produce inconsistent long-term outcomes, and seldom prioritise personal recovery as a primary treatment goal. We aimed to investigate the effectiveness of Talking with Voices (TwV), a lived-experience informed intervention in which therapists engage in direct dialogue with voices, in improving both personal recovery and clinical outcomes for individuals experiencing persistent and distressing voice hearing.</p><p><strong>Methods: </strong>Talking with Voices-II was a rater-blinded, parallel-arm, multisite, randomised controlled trial to test the efficacy and underlying mechanisms of TwV therapy compared with treatment as usual (TAU) in community-based National Health Service mental health services across four UK sites. Participants with SMHPs who experienced distressing voices were randomly assigned (1:1), using random-sized blocks, stratified by site and presence of schizophrenia diagnosis, to receive either TwV plus TAU or TAU alone. Therapy was provided in up to 26 sessions over 8 months, and assessments were conducted at baseline, 8 months, and 14 months by assessors masked to treatment allocation. The primary outcome was the Questionnaire about the Process of Recovery score at 8 months, a self-reported measure of personal recovery in psychosis. Secondary outcomes were voice-related measures, self-beliefs, dissociation, and post-traumatic stress disorder (PTSD) symptoms. The primary analysis followed the intention-to-treat principle, and moderation and mediation were prespecified in the statistical analysis plan. The mediation analysis was carried out using the mediate command, utilising bootstrapping to obtain percentile CIs. The trial was prospectively registered with ISRCTN, ISRCTN15897915, and all research and clinical procedures were co-led by individuals with lived experience of psychosis.</p><p><strong>Findings: </strong>Between Sept 1, 2023, and June 30, 2025, we screened 1316 participants, of whom 309 consented, completed baseline assessments, and were randomly assigned to either TwV plus TAU (n=156) or TAU alone (n=153). The mean age of participants was 41·1 years (SD 13·1). 159 (52%) participants were men, 145 (47%) were women, and four (1%) were another gender, and one preferred not to say; 222 (72%) participants were White. At 8 months, personal recovery was significantly better in the TwV group than in the TAU group (adjusted difference 6·97 [95% CI 5·00-8·95]; p<0·0001; standardised effect size [SES] 0·63). Significant differences favouring TwV were found for 12 (80%) of 15 of secondary outcomes, unadjusted for multiple testing, including all voice-related measures, negative self-beliefs, and PTSD outcomes, with SES ranging from 0·18 to 0·86. There were no effects on dissociation-related measures or positive self-beliefs (SES ranging from <0·01 to 0·16). An effect was still evident on personal recovery at 14 months, although reduced (adjusted difference 3·55 [0·96-6·14]; p=0·0073; SES=0·32). 55 serious adverse events occurred in 36 participants in the TwV group, and 60 serious adverse events occurred in 45 participants in the TAU group, none of which were deemed definitely related to the therapy or research procedures.</p><p><strong>Interpretation: </strong>TwV significantly improves personal recovery, showing efficacy for individuals with SMHPs who experience distressing voices. Further research comparing TwV with an active control and evaluating its implementation in routine care settings is warranted.</p><p><strong>Funding: </strong>National Institute for Health and Care Research.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":""},"PeriodicalIF":21.1000,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2215-0366(26)00330-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Existing treatments for auditory hallucinations (hereafter voice hearing) among people with serious mental health problems (SMHPs; diagnoses include schizophrenia spectrum disorders, bipolar disorders, and personality disorders) show only modest clinical benefits, produce inconsistent long-term outcomes, and seldom prioritise personal recovery as a primary treatment goal. We aimed to investigate the effectiveness of Talking with Voices (TwV), a lived-experience informed intervention in which therapists engage in direct dialogue with voices, in improving both personal recovery and clinical outcomes for individuals experiencing persistent and distressing voice hearing.

Methods: Talking with Voices-II was a rater-blinded, parallel-arm, multisite, randomised controlled trial to test the efficacy and underlying mechanisms of TwV therapy compared with treatment as usual (TAU) in community-based National Health Service mental health services across four UK sites. Participants with SMHPs who experienced distressing voices were randomly assigned (1:1), using random-sized blocks, stratified by site and presence of schizophrenia diagnosis, to receive either TwV plus TAU or TAU alone. Therapy was provided in up to 26 sessions over 8 months, and assessments were conducted at baseline, 8 months, and 14 months by assessors masked to treatment allocation. The primary outcome was the Questionnaire about the Process of Recovery score at 8 months, a self-reported measure of personal recovery in psychosis. Secondary outcomes were voice-related measures, self-beliefs, dissociation, and post-traumatic stress disorder (PTSD) symptoms. The primary analysis followed the intention-to-treat principle, and moderation and mediation were prespecified in the statistical analysis plan. The mediation analysis was carried out using the mediate command, utilising bootstrapping to obtain percentile CIs. The trial was prospectively registered with ISRCTN, ISRCTN15897915, and all research and clinical procedures were co-led by individuals with lived experience of psychosis.

Findings: Between Sept 1, 2023, and June 30, 2025, we screened 1316 participants, of whom 309 consented, completed baseline assessments, and were randomly assigned to either TwV plus TAU (n=156) or TAU alone (n=153). The mean age of participants was 41·1 years (SD 13·1). 159 (52%) participants were men, 145 (47%) were women, and four (1%) were another gender, and one preferred not to say; 222 (72%) participants were White. At 8 months, personal recovery was significantly better in the TwV group than in the TAU group (adjusted difference 6·97 [95% CI 5·00-8·95]; p<0·0001; standardised effect size [SES] 0·63). Significant differences favouring TwV were found for 12 (80%) of 15 of secondary outcomes, unadjusted for multiple testing, including all voice-related measures, negative self-beliefs, and PTSD outcomes, with SES ranging from 0·18 to 0·86. There were no effects on dissociation-related measures or positive self-beliefs (SES ranging from <0·01 to 0·16). An effect was still evident on personal recovery at 14 months, although reduced (adjusted difference 3·55 [0·96-6·14]; p=0·0073; SES=0·32). 55 serious adverse events occurred in 36 participants in the TwV group, and 60 serious adverse events occurred in 45 participants in the TAU group, none of which were deemed definitely related to the therapy or research procedures.

Interpretation: TwV significantly improves personal recovery, showing efficacy for individuals with SMHPs who experience distressing voices. Further research comparing TwV with an active control and evaluating its implementation in routine care settings is warranted.

Funding: National Institute for Health and Care Research.

对话疗法加常规治疗与常规治疗在英国患有痛苦和持续性幻听的成年人中的对比(与声音交谈- ii):一项随机对照试验。
背景:现有治疗严重精神健康问题(SMHPs;诊断包括精神分裂症谱系障碍、双相情感障碍和人格障碍)患者的幻听(以下简称声音听力)的方法仅显示出适度的临床疗效,产生不一致的长期结果,并且很少将个人康复作为主要治疗目标。我们的目的是调查与声音交谈(TwV)的有效性,TwV是一种实时体验的知情干预,治疗师与声音直接对话,改善持续和痛苦的声音听力患者的个人恢复和临床结果。方法:与声音交谈- ii是一项非盲法、平行组、多地点、随机对照试验,旨在测试TwV治疗与常规治疗(TAU)在英国四个地点的社区国家卫生服务精神卫生服务中的疗效和潜在机制。经历痛苦声音的SMHPs参与者被随机分配(1:1),使用随机大小的块,根据地点和精神分裂症诊断的存在进行分层,接受TwV加TAU或单独接受TAU。治疗在8个月内提供了多达26个疗程,评估人员在基线、8个月和14个月进行了评估,评估人员对治疗分配进行了掩盖。主要结果是关于8个月恢复过程的问卷得分,这是一种自我报告的衡量个人精神病恢复的方法。次要结局是语音相关测量、自我信念、分离和创伤后应激障碍(PTSD)症状。初步分析遵循意向治疗原则,在统计分析计划中预先规定了调节和中介作用。使用mediation命令进行中介分析,利用bootstrapping获得百分位数ci。该试验在ISRCTN进行了前瞻性注册,注册号为ISRCTN15897915,所有研究和临床程序均由有精神病生活经历的个体共同领导。研究结果:在2023年9月1日至2025年6月30日期间,我们筛选了1316名参与者,其中309人同意并完成了基线评估,并随机分配到TwV加TAU (n=156)或TAU单独(n=153)。参与者的平均年龄为41.1岁(SD 13.1)。159名(52%)参与者为男性,145名(47%)参与者为女性,4名(1%)参与者为其他性别,其中一人不愿透露姓名;222名(72%)参与者为白人。8个月时,TwV组的个人恢复明显优于TAU组(调整差值为6.97 [95% CI为5.00 - 8.95]);p解释:TwV显著改善了个人恢复,对经历痛苦声音的SMHPs个体有效。进一步的研究比较TwV与主动控制,并评估其在日常护理环境中的实施是必要的。资助:国家卫生和保健研究所。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Psychiatry
Lancet Psychiatry PSYCHIATRY-
CiteScore
58.30
自引率
0.90%
发文量
0
期刊介绍: The Lancet Psychiatry is a globally renowned and trusted resource for groundbreaking research in the field of psychiatry. We specialize in publishing original studies that contribute to transforming and shedding light on important aspects of psychiatric practice. Our comprehensive coverage extends to diverse topics including psychopharmacology, psychotherapy, and psychosocial approaches that address psychiatric disorders throughout the lifespan. We aim to channel innovative treatments and examine the biological research that forms the foundation of such advancements. Our journal also explores novel service delivery methods and promotes fresh perspectives on mental illness, emphasizing the significant contributions of social psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书